Mirae Asset Global Investments Co. Ltd. Has $11.89 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Mirae Asset Global Investments Co. Ltd. decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 0.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 94,570 shares of the medical research company’s stock after selling 366 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Natera were worth $11,889,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of NTRA. Itau Unibanco Holding S.A. bought a new position in Natera during the second quarter worth $28,000. Quarry LP raised its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC boosted its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. Tobam bought a new position in shares of Natera during the 2nd quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Natera in the 1st quarter valued at about $83,000. Institutional investors own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the transaction, the insider now owns 299,441 shares in the company, valued at approximately $34,082,374.62. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total value of $185,946.90. Following the completion of the transaction, the chief financial officer now owns 71,955 shares in the company, valued at $7,170,315.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total transaction of $307,314.00. Following the completion of the transaction, the insider now directly owns 299,441 shares of the company’s stock, valued at approximately $34,082,374.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,770 shares of company stock worth $5,351,448 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Stock Down 1.3 %

NTRA stock opened at $117.67 on Monday. The stock has a market cap of $14.45 billion, a P/E ratio of -37.71 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The stock’s fifty day simple moving average is $123.24 and its two-hundred day simple moving average is $111.44. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $133.54.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.97) earnings per share. Analysts expect that Natera, Inc. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. TD Cowen increased their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Robert W. Baird lifted their price target on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Canaccord Genuity Group boosted their price target on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, BTIG Research upped their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $124.44.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.